A Phase 3 interventional study of Oxybutynin and Venlafaxine in Breast Cancer and Hot Flash Due to Medication, sponsored by Reinier de Graaf Groep. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Reinier de Graaf Groep · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 390 studies in Breast Neoplasms with a site in Netherlands — 69 open to participants now, 115 under way, 35 of them phase 3. Breast Neoplasms · Netherlands.
Among the 390 studies in Breast Neoplasms with a site in Netherlands, this one is the 125th largest by planned enrollment of the 314 interventional ones that give a count, is one of 19 that started in 2024, is one of 105 in phase 3, reaches primary completion later than 88 of the 114 other live ones, and was the 341st registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →69 of the 390 studies in Breast Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+ · Women only
Novartis Pharmaceuticals · Sites in Netherlands
Ages 18–100
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 6 more countries
Ages 18+
UMC Utrecht · Sites in Netherlands, Denmark, Germany and 1 more country
Ages 35+
SPCTR · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
390 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 57 · Phase 2 88 · Phase 3 111 · Phase 4 6
First in 1992; this study’s year is marked. 19 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 189 across the 314 interventional studies, 205 across the 72 observational. Of the 245 that completed or were terminated, 71 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
153 of 390 have an industry lead sponsor. The 10 most frequent:
Reinier de Graaf Groep is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Reinier de Graaf Groep has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Breast Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05774951Phase 3AstraZenecaA Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | 2027-04-20 |
| NCT06312176Phase 3Merck Sharp & Dohme LLCA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | 2027-07-11 |
| NCT07062965Phase 3PfizerA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | 2027-07-22 |
| NCT05514054Phase 3Eli Lilly and CompanyA Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | 2027-10 |
| NCT05950945Phase 3Daiichi SankyoTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | 2027-10-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 390 studies in Breast Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this randomized intrapatient cross-over study is to assess the efficacy of oxybutynin versus venlafaxine in reducing hot flashes in women using endocrine therapy after breast cancer.
The objectives it aims to answer are:
Participants will fill-out a patient diary during 15 weeks total on a daily basis and receive an (online) questionnaire three times total.
Researchers will compare two groups (venlafaxine group versus oxubutynine group) to assess its efficacy concerning hot flashes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this open-label randomized controlled intrapatient cross-over study patients are randomly assigned to one of the two treatment groups. After a one week baseline period, group 1 starts with venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks followed by a two-week wash-out period (no medication), hereafter the group starts with oxybutynin 5 mg twice per day for 6 weeks total.
Drug: Oxybutynin · Drug: Venlafaxine
After a one week baseline period, group 2 starts with oxybutynin 5 mg twice per day for 6 weeks total followed by a two-week wash-out period (no medication), hereafter the group starts with venlafaxine 37.5 mg once daily for 7 days followed by 75mg once daily for 5 weeks.
Drug: Oxybutynin · Drug: Venlafaxine
Oxybutynin 5 mg twice per day for 6 weeks
Venlafaxine 37.5 mg once daily for 7 days followed by 75 mg once daily for 5 weeks
Number and severity of hot flashes
Number and severity of hot flashes during 6-weeks of therapy measured by the Hot Flash Diary.
Time frame: 15 weeks total
Quality of life and health status
Quality of life and health status at baseline and after 6 weeks of treatment measured by the EORTC-QLQ-C30
Time frame: 15 weeks total
Adverse effects of treatments
Adverse effects of treatments weekly measured by the National Cancer Institute Common Toxicity Criteria scale, version 5
Time frame: 15 weeks total
Sleep quality
Sleep quality at baseline and after 6 weeks of treatment measured by the Groningen Sleep Quality Scale (GSQ)
Time frame: 15 weeks total
Anxiety and depression
Anxiety and depression measured at baseline and after 6 weeks of treatment with the Hospital Anxiety and Depression Scale (HADS)
Time frame: 15 weeks total
Sexual function
Sexual function measured at baseline and after 6 weeks of treatment with the Sexual Activity Questionnaire (SAQ)
Time frame: 15 weeks total
Cognitive function
Cognitive function measured at baseline and after 6 weeks of treatment with the 6-item cognitive impairment test (6-CIT)
Time frame: 15 weeks total
Adherence
Ask patients the following question after 6 weeks of treatment: 'Would you like to continue the endocrine therapy for the recommended duration of therapy taking the current medication (oxybutynin or venlafaxine) given the number and severity of hot flashes you experience during the last week?'
Time frame: 15 weeks total
Preference
Ask patients the following question after 6 weeks of the final treatment: 'Do you have a preference taking the medication from study period 1 or study period 2?'
Time frame: 15 weeks total
Plan to share: Yes — Study protocol, anonymised database and study results may be available on request, after assessment of the reason for request by the study investigators.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Jan 2029, 50 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 50 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Oxybutynin · Venlafaxine
Reinier de Graaf Groep